Skip to content
Evigrade
CriticalClass Ia antiarrhythmic with antimuscarinic activity×Prokinetic, peripheral dopamine D2 receptor antagonist

Updated · Methodology

Mechanism

Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day and with QT-prolonging drugs (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Disopyramide, a class IA antiarrhythmic, can also prolong the QT interval and cause ventricular arrhythmias, including torsade de pointes (disopyramide SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The Spanish domperidone SmPC explains that such combinations raise the risk of QT prolongation through pharmacodynamic or pharmacokinetic interactions. It lists disopyramide among the contraindicated class IA antiarrhythmics (AEMPS). CYP3A4 metabolises both drugs. According to the Spanish disopyramide SmPC, drugs that this enzyme metabolises may compete with disopyramide for it, and their blood levels may rise (disopyramide and domperidone SmPCs, AEMPS). The documents do not say how much the domperidone level changes.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Disopyramide can cause ventricular tachycardia, ventricular fibrillation and torsade de pointes, which lead to palpitations, dizziness and fainting (disopyramide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). At toxic disopyramide levels, the QT interval lengthens markedly, the QRS complex widens and heart block appears. Torsade de pointes can cause repeated fainting (disopyramide SmPC, AEMPS, overdose section). With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone SmPC, AEMPS). Disopyramide-induced arrhythmias are more likely with low potassium, severe structural heart disease or an already prolonged QT (disopyramide SmPC, AEMPS). With domperidone, the risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).

Management

The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names disopyramide (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish disopyramide SmPC contraindicates disopyramide with other drugs that can cause ventricular arrhythmias, especially torsade de pointes. Domperidone is not in its lists of such drugs (disopyramide SmPC, AEMPS). Disopyramide is contraindicated in pre-existing long QT, and domperidone in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (disopyramide and domperidone SmPCs, AEMPS). During disopyramide treatment, monitor the QT interval and QRS duration and stop disopyramide if they lengthen by more than 25% (disopyramide SmPC, AEMPS). Monitor potassium and correct abnormal levels (disopyramide SmPC, AEMPS). The US label asks for this before starting disopyramide (disopyramide label, US Food and Drug Administration, FDA). If domperidone and disopyramide have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Disopyramide

Other interactions with Domperidone